Patents by Inventor Hidde L. Ploegh

Hidde L. Ploegh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12331311
    Abstract: Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: June 17, 2025
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Lee Kim Swee, Hidde L. Ploegh
  • Publication number: 20250144228
    Abstract: Provided herein are conjugate molecules comprising an antibody or antibody fragment capable of binding polyclonal immnunoglobulins within a subject. Such conjugates are useful for recruiting immune cells of the subject to one or more cell types that are targeted by the conjugate. Also provided herein are compositions comprising the conjugates, including pharmaceutical compositions that may be administered to a subject, for such a purpose as to treat or prevent a disease.
    Type: Application
    Filed: January 19, 2023
    Publication date: May 8, 2025
    Applicant: The Children's Medical Center Corporation
    Inventors: Hidde L. Ploegh, Xin Liu, Novalia Pishesha, Elisha Verhaar
  • Publication number: 20240325575
    Abstract: Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specifically conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.
    Type: Application
    Filed: June 7, 2024
    Publication date: October 3, 2024
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Mohammad Rashidian, Hidde L. Ploegh
  • Patent number: 12048753
    Abstract: Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specifically conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.
    Type: Grant
    Filed: October 1, 2016
    Date of Patent: July 30, 2024
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Mohammad Rashidian, Hidde L. Ploegh
  • Patent number: 11992505
    Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: May 28, 2024
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha
  • Patent number: 11878063
    Abstract: Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: January 23, 2024
    Assignees: Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Ross Cheloha, Hidde L. Ploegh, Thomas J. Gardella
  • Patent number: 11850216
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: December 26, 2023
    Assignees: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Publication number: 20230348605
    Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
    Type: Application
    Filed: February 28, 2023
    Publication date: November 2, 2023
    Applicants: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical Research
    Inventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu J. Xie
  • Publication number: 20230233701
    Abstract: Provided herein are compositions comprising VHH conjugates and their uses in treating diseases.
    Type: Application
    Filed: June 2, 2021
    Publication date: July 27, 2023
    Applicant: Children's Medical Center Corporation
    Inventors: Novalia Pishesha, Hidde L. Ploegh, Thibault Harmand
  • Patent number: 11597769
    Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 7, 2023
    Assignees: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical Research
    Inventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu Joy Xie
  • Patent number: 11492590
    Abstract: Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 8, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Lee Kim Swee, Hidde L. Ploegh
  • Publication number: 20220175833
    Abstract: Provided herein are engineered cells that comprising a chimeric antigen receptor comprising an extracellular target-binding moiety and an intracellular signaling domain; and secrets a heavy-chain antibody (VHH) or a VHH fusion protein. Methods of using the engineered cell to treat a disease (e.g., cancer or autoimmune disease) are also provided.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Applicants: Children's Medical Center Corporation, Massachusetts Institute of Technology
    Inventors: Yushu J. Xie, Hidde L. Ploegh
  • Patent number: 11266695
    Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 8, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Sherry Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha
  • Publication number: 20220032257
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Application
    Filed: September 20, 2021
    Publication date: February 3, 2022
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 11154833
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 26, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 11028185
    Abstract: Methods and reagents for the installation of click chemistry handles on target proteins are provided, as well as modified proteins comprising click chemistry handles. Further, chimeric proteins, for example, bi-specific antibodies, that comprise two proteins conjugated via click chemistry, as well as methods for their generation and use are disclosed herein.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 8, 2021
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Hidde L. Ploegh, Martin D. Witte, Nicholas C. Yoder
  • Publication number: 20200384137
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Application
    Filed: January 8, 2020
    Publication date: December 10, 2020
    Applicants: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Publication number: 20200316217
    Abstract: Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.
    Type: Application
    Filed: March 5, 2020
    Publication date: October 8, 2020
    Applicants: Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Ross Cheloha, Hidde L. Ploegh, Thomas J. Gardella
  • Publication number: 20200206269
    Abstract: Multi-step methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express fusion proteins comprising an antigen binding protein which allows the red blood cell to bind a toxin or an antigen of a pathogen. Also described herein are methods for neutralizing a toxin or pathogen in a subject by administering enucleated red blood cells that express any of the fusion proteins provided herein.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 2, 2020
    Applicants: Whitehead Institute for Biomedical Research, Trustees of Tufts College
    Inventors: Harvey Lodish, Nai-Jia Huang, Novalia Pishesha, Hidde L. Ploegh, Charles Shoemaker
  • Publication number: 20200069736
    Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.
    Type: Application
    Filed: September 16, 2019
    Publication date: March 5, 2020
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha